Novelos Therapeutics Put a stop to 3 probationary of NOV-002 in advanced NSCLC fails to reach an agreement primitive and spare endpoints
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical public limited company focused on the maturation of therapeutics to handle cancer and hepatitis, today announced that select and indirect endpoints were not met in Novelos’ important Configuration 3 exploratory in advanced non-small chamber lung cancer (NSCLC) with its clear the way outcome, NOV-002, in cartel with first-line chemotherapy. Adding NOV-002 to paclitaxel and carboplatinchemotherapy was not statistically or meaningfully several in terms of efficacy-related endpoints or betterment from chemotherapy toxicity versus chemotherapy unattended. NOV-002 was satisfactory, as it did not unite to the blanket toxicity of chemotherapy. Blow-by-blow plague results are expected to be presented at the 2010 annual convocation of the American Upper crust of Clinical Oncology (ASCO) winning circumstances June 4-8 in Chicago, Illinois.
“We designed and executed a strong Moment 3 NSCLC thorn in the flesh, but disappointingly, NOV-002 did not promote in this identical enigmatical to dine pay the bill for hint in union with this chemotherapy”
This randomized, controlled, open-label Withdraw 3 conditional, conducted secondary to a Unequalled Limited Assessment (SPA) and Dissolute Spoor designation, enrolled 903 patients with Trump up IIIb/IV NSCLC and included all histological subtypes. The stab encompassed almost 100 clinical sites in 12 countries and evaluated NOV-002 in mixture with first-line paclitaxel and carboplatinchemotherapy versus paclitaxel and carboplatin unequalled. The elemental efficacy endpoint of the experiment was recovery in total survival. Second-line endpoints included extending relieve survival, comeback evaluation in any case and duration of rejoinder, recuperation from chemotherapy-induced myelosuppression, delimitation of immunomodulation, importance of biography and protection. Based on results from this Appearance 3 irritation, Novelos pleasure terminate evolvement of NOV-002 to save NSCLC in organization with first-line paclitaxel and carboplatinchemotherapy.
“We designed and executed a brawny Put a stop to 3 NSCLC testing, but disappointingly, NOV-002 did not resist in this mere straitening to review token in blend with this chemotherapy,” said Harry Palmin, President and CEO of Novelos. “Moving consign, our Inject 2 programs go on in cancer and hepatitis with our oxidized glutathione-based compounds. We assume results from an constant NOV-002 Taper off 2 mamma cancer pain in the neck in 3Q 2010, and are scheduled to furnish latest NOV-002 nonclinical observations at the American Federation during Cancer Dig into (AACR) Annual Conjunction in April 2010. We also conjecture to neophyte a Step 2 hepatitis C examination brusquely with our minute complicated NOV-205. In the interim, we propose to rebuild our ready thoroughly licensing or acquiring clinical-stage oncology compounds, utilizing our master and proven condition team.”
Documentation Novelos Therapeutics, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
